Press releases
- Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
- Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
- Neurocrine Biosciences to Participate at Investor Conferences in March
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
More ▼
Key statistics
On Friday, Neurocrine Biosciences Inc (NB3:FRA) closed at 128.25, -5.25% below its 52-week high of 135.35, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 128.25 |
---|---|
High | 128.25 |
Low | 128.25 |
Bid | 126.85 |
Offer | 127.20 |
Previous close | 128.60 |
Average volume | 173.20 |
---|---|
Shares outstanding | 100.58m |
Free float | 99.31m |
P/E (TTM) | 56.66 |
Market cap | 13.86bn USD |
EPS (TTM) | 2.43 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:01 BST.
More ▼